We propose to establish a Comprehensive Sickle Cell Disease Center which will have as its major objectives: 1) Improved care for patients with sickle cell disease residing in the catchment area of Duke University Medical Center, 2) Clinical Research on the effects of sickle cell disease on: a) metabolism of glucose by the brain, b) cardiopulmonary function, c) aseptic necrosis of the hip, 3) Development and institution of information-education programs about sickle cell syndromes for patients, heterozygotes, families, physicians, nurses, other health professionals, and the community at large. These information-education programs will be linked to sickle cell screening directed at education guidance, and disease detection and will be interwoven in the presently active State Sickle Cell Program and community based Sickle Cell Programs. 4) Study of basic scientific problems in sickle cell disease including: a) characterization and influence of hemoglobin geneotype, b) study of allosteric effectors of hemoglobin function, 3) effects of HbS geleation on ionic red cell membrane transport, d) studies of red cell membrane fludity. In order to diffuse the relevant programs throughout the State and to obtain input from the community, we will work with the State Program and two active community-based Sickle Cell groups. We will cooperate fully with other Comprehensive Centers involved in the National Sickle Cell Program.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Comprehensive Center (P60)
Project #
5P60HL028391-09
Application #
3108521
Study Section
Special Emphasis Panel (SRC (JB))
Project Start
1983-04-01
Project End
1993-03-31
Budget Start
1991-04-01
Budget End
1992-03-31
Support Year
9
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Ariens, Robert A S; Lai, Thung-Shenq; Weisel, John W et al. (2002) Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 100:743-54
Ware, Russell E; Eggleston, Barry; Redding-Lallinger, Rupa et al. (2002) Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 99:10-4
Thompson Jr, Robert J; Gustafson, Kathryn E; Bonner, Melanie J et al. (2002) Neurocognitive development of young children with sickle cell disease through three years of age. J Pediatr Psychol 27:235-44
Slaughter, T F; Sreeram, G; Sharma, A D et al. (2001) Reversible shear-mediated platelet dysfunction during cardiac surgery as assessed by the PFA-100 platelet function analyzer. Blood Coagul Fibrinolysis 12:85-93
Lai, T S; Hausladen, A; Slaughter, T F et al. (2001) Calcium regulates S-nitrosylation, denitrosylation, and activity of tissue transglutaminase. Biochemistry 40:4904-10
Ataga, K I; Orringer, E P (2000) Renal abnormalities in sickle cell disease. Am J Hematol 63:205-11
Ataga, K I; Orringer, E P (2000) Bone marrow necrosis in sickle cell disease: a description of three cases and a review of the literature. Am J Med Sci 320:342-7
Kinney, T R; Helms, R W; O'Branski, E E et al. (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94:1550-4
Lai, T S; Slaughter, T F; Peoples, K A et al. (1999) Site-directed mutagenesis of the calcium-binding site of blood coagulation factor XIIIa. J Biol Chem 274:24953-8
Slentz-Kesler, K A; Hale, L P; Kaufman, R E (1998) Identification and characterization of K12 (SECTM1), a novel human gene that encodes a Golgi-associated protein with transmembrane and secreted isoforms. Genomics 47:327-40

Showing the most recent 10 out of 78 publications